Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Journal Article
| Authors: | Khan, R. B.; Shi, W.; Thaler, H. T.; Deangelis, L. M.; Abrey, L. E. |
| Article Title: | Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? |
| Abstract: | Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity. |
| Keywords: | adult; cancer survival; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; case control study; case-control studies; dose response; drug efficacy; primary central nervous system lymphoma; methotrexate; drug megadose; neurotoxicity; antimetabolites, antineoplastic; drug effect; dose-response relationship, drug; retrospective study; central nervous system neoplasms; lymphoma; cognitive defect; primary cns lymphoma; motor dysfunction; disease control; leukoencephalopathy; injections, spinal; drug indication; nervous system; intrathecal chemotherapy; meningocele; humans; human; male; female; article |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 58 |
| Issue: | 2 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2002-06-01 |
| Start Page: | 175 |
| End Page: | 178 |
| Language: | English |
| DOI: | 10.1023/a:1016077907952 |
| PUBMED: | 12164690 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
576De Angelis -
121Shi -
7Khan -
278
Abrey -
245Thaler
Related MSK Work